RespireRx Pharmaceuticals Inc (fka RSPI)

[gfp927z]

Neuro, So a pharma like Lilly or Shire would have no qualms about partnering CX-1739 for ADHD or SA/RD, even though the same compound is already partnered with Samyang for Neurodegenerative in Asia?

Didn't we have a similar discussion years ago about CX-516? At that time CX-516 was the only clinic ready compound Cortex had (as CX-1739 is now), but you said that it was very unlikely to find a 2nd partner for CX-516 because that pharma wouldn't have enough control, and trouble in the one pharma's trial would reflect back negatively to the other pharma's trial.

I don't see how this situation with CX-1739 is any different. Otherwise, why not just develop one compound and partner it off to 5 different pharmas for different indications?